Acute lung injury: The therapeutic role of Rho kinase inhibitors

Farshad Abedi, A. Wallace Hayes, Russel Reiter, Gholamreza Karimi

Research output: Contribution to journalReview articlepeer-review

69 Scopus citations


Acute lung injury (ALI) is a pulmonary illness with high rates of mortality and morbidity. Rho GTPase and its downstream effector, Rho kinase (ROCK), have been demonstrated to be involved in cell adhesion, motility, and contraction which can play a role in ALI. The electronic databases of Google Scholar, Scopus, PubMed, and Web of Science were searched to obtain relevant studies regarding the role of the Rho/ROCK signaling pathway in the pathophysiology of ALI and the effects of specific Rho kinase inhibitors in prevention and treatment of ALI. Upregulation of the RhoA/ROCK signaling pathway causes an increase of inflammation, immune cell migration, apoptosis, coagulation, contraction, and cell adhesion in pulmonary endothelial cells. These effects are involved in endothelium barrier dysfunction and edema, hallmarks of ALI. These effects were significantly reversed by Rho kinase inhibitors. Rho kinase inhibition offers a promising approach in ALI [ARDS] treatment.

Original languageEnglish (US)
Article number104736
JournalPharmacological Research
StatePublished - May 2020
Externally publishedYes


  • Acute lung injury
  • Endothelial cell
  • Fasudil
  • Fasudil (PubChem CID: 3547)
  • Netarsudil (PubChem CID: 66599893)
  • Oleic acid (PubChem CID: 445639)
  • Paraquat (PubChem CID: 15939)
  • ROCK
  • Rho kinase inhibitor
  • Ripasudil (PubChem CID: 9863672)
  • Simvastatin (PubChem CID: 54454)
  • Y-27632 (PubChem CID: 9901617)

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Acute lung injury: The therapeutic role of Rho kinase inhibitors'. Together they form a unique fingerprint.

Cite this